The review date of the new treatment for diabetes, inhaled insulin, is extended by three months by MannKind Corp and the U.S. Food and Drug Administration less than a week after the FDA recommended approving the treatment, Reuters reports.
The treatment Afrezza consists of a small inhaler that delivers insulin powder to the lungs. This enables diabetics to bypass injected insulin. The FDA said longer-term studies were necessary to gauge the risk of lung cancer and other possible side effects.
MannKind announced Monday that the new review date for Afrezza is set for July 15. If approved, this would be the first inhaled insulin treatment available in the U.S. since 2006.
Read the full story here: MannKind says FDA delays decision on inhaled insulin treatment